Sermorelin

Research-Documented Benefits

• Growth Hormone Stimulation — Sermorelin (GHRH 1-29) stimulates natural, pulsatile GH release from the anterior pituitary, preserving the physiological feedback axis.
• Body Composition — Research demonstrates improvements in lean muscle mass and reductions in adipose tissue in GH-deficient models.
• Bone Density Support — Studies show enhanced osteoblast activity and improved bone mineral density with sustained sermorelin administration in preclinical models.
• Sleep Quality — Documented improvement in slow-wave sleep duration, which correlates with endogenous GH secretion peaks during deep sleep cycles.
• Age-Related GH Decline — Research in aged animal models demonstrates partial restoration of youthful GH pulsatility patterns without supraphysiological peaks.

Mechanism of Action

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous GHRH (growth hormone releasing hormone), which is the biologically active fragment responsible for GH secretion.

Primary Pathways

• GHRH Receptor Binding — Binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells, activating adenylyl cyclase via Gs-protein coupling and increasing intracellular cAMP.
• Pulsatile GH Release — Stimulates physiological, pulsatile GH secretion that follows natural circadian patterns, rather than producing the flat, elevated GH levels seen with exogenous GH administration.
• Somatostatin Feedback — Preserves the somatostatin negative feedback loop, so GH release is self-limiting and does not reach supraphysiological concentrations.
• IGF-1 Axis Activation — GH released by sermorelin stimulates hepatic IGF-1 production, which mediates many downstream anabolic effects on muscle, bone, and other tissues.

Sermorelin's mechanism preserves the hypothalamic-pituitary feedback axis, distinguishing it from direct GH administration and providing a more physiological approach to GH secretion research.

Research Protocol Guidelines

All protocols described are for in vitro and in vivo research purposes only. Not for human use.

Reconstitution

Reconstitute lyophilized sermorelin with bacteriostatic water. For a 2 mg vial, adding 2 mL yields 1 mg/mL (1,000 mcg/mL).

Research Dosing (Preclinical Literature)

• GH stimulation studies: 1-2 mcg/kg subcutaneously, typically administered in the evening to coincide with natural GH pulsatility
• Chronic studies: Daily subcutaneous administration for 6-12 months in aging research models
• GH stimulation test: 1 mcg/kg IV bolus with serial GH sampling at 15-minute intervals over 90 minutes

Storage

Store lyophilized form at 2-8°C (may also be stored at -20°C for extended periods). Reconstituted solution at 2-8°C, use within 14 days. Sermorelin is relatively fragile; avoid room temperature exposure.

Safety & Handling Information

For research use only. Not intended for human or veterinary diagnostic or therapeutic use.

Storage Requirements

• Lyophilized: 2-8°C (short-term) or -20°C (long-term)
• Reconstituted: 2-8°C, use within 14 days
• Sermorelin is temperature-sensitive; avoid room temperature storage

Preclinical & Clinical Safety Profile

Sermorelin was previously FDA-approved (Geref Diagnostic) and has an established clinical safety database. Injection site reactions (redness, swelling) are the most commonly reported events.

Known Considerations

• Contraindicated in research models with active neoplasia, as GH/IGF-1 may promote tumor growth
• Anti-sermorelin antibodies may develop with chronic administration, potentially reducing efficacy over time
• Cortisol, prolactin, and TSH levels are generally unaffected at standard doses
• Hypoglycemia monitoring recommended in diabetic research models due to GH-mediated metabolic effects

Handling

Standard laboratory PPE. Store immediately upon receipt. Reconstitute with cold bacteriostatic water.

Frequently Asked Questions